PMID- 35688904 OWN - NLM STAT- MEDLINE DCOM- 20220715 LR - 20220715 IS - 1432-0584 (Electronic) IS - 0939-5555 (Linking) VI - 101 IP - 8 DP - 2022 Aug TI - Adverse events in lymphoma patients treated with phosphoinositide 3 kinase Inhibitor in clinical trials: a meta-analysis. PG - 1741-1753 LID - 10.1007/s00277-022-04876-x [doi] AB - BACKGROUND: Malignant lymphomas are one of the most common cancers worldwide and with high biologic heterogeneity, while the phosphoinositide 3 kinase (PI3K)/mTOR pathway is crucial in maintaining cell growth and survival both in physiological and in pathological conditions (i.e., lymphoma). PI3K inhibitors have been proven to be effective in several subtypes of lymphomas. However, the high incidence of treatment-related adverse events as well as the special safety profile in PI3K inhibitors draws great attention. Thus, this meta-analysis was conducted to compare adverse events in PI3K inhibitors to conventional regimens in lymphoma patients. METHODS: Articles were retrieved from PubMed, Cochrane, and Embase to identify randomized controlled trials and phase III clinical trials that used PI3K inhibitors comparing with non-PI3K inhibitors in lymphoma patients. To achieve the appropriate results, we calculated the risk ratio and 95% confidence intervals. RESULTS: Four trials with 1399 patients that met our criteria were included. The PI3K inhibitors group significantly increased the risk of all-grade adverse events (AEs) (RR 0.95, 95% CI: 0.92-0.98) and high-grade AEs (RR 0.63, 95% CI: 0.57-0.70), compared with the non-PI3K inhibitors group. Besides, the incidence of neutropenia (RR 0.81, 95% CI: 0.74-0.90), pneumonia (RR 0.62, 95% CI: 0.46-0.83), and diarrhea (RR 0.40, 95% CI: 0.32-0.49) were significantly high in the PI3Ki group, while the incidence of anemia (RR 0.78, 95% CI: 0.50-1.20) and thrombocytopenia (RR 0.85, 95% CI: 0.51-1.42) had no statistic significant. CONCLUSION: PI3K inhibitors increased the risk of certain AEs in lymphoma patients. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Shan, Weihang AU - Shan W AD - Department of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Xiamen University, Xiamen, 361102, People's Republic of China. AD - Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, 361102, People's Republic of China. FAU - Wu, Guixiang AU - Wu G AD - Department of Hematology, Jieyang People's Hospital (JieYang Affiliated Hospital, Sun Yat-Sen University), Jieyang, Guangdong, People's Republic of China. FAU - Huang, Yueting AU - Huang Y AD - Department of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Xiamen University, Xiamen, 361102, People's Republic of China. AD - Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, 361102, People's Republic of China. FAU - Zeng, Hanyan AU - Zeng H AD - Department of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Xiamen University, Xiamen, 361102, People's Republic of China. FAU - Xia, Weilin AU - Xia W AD - Department of Hematology, Jieyang People's Hospital (JieYang Affiliated Hospital, Sun Yat-Sen University), Jieyang, Guangdong, People's Republic of China. jyxiaweilin@163.com. FAU - Lin, Zhijuan AU - Lin Z AD - Department of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Xiamen University, Xiamen, 361102, People's Republic of China. zjuan_lin@126.com. AD - Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, 361102, People's Republic of China. zjuan_lin@126.com. FAU - Xu, Bing AU - Xu B AD - Department of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Xiamen University, Xiamen, 361102, People's Republic of China. xubing@xmu.edu.cn. AD - Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, 361102, People's Republic of China. xubing@xmu.edu.cn. LA - eng GR - 82170180/National Natural Science Foundation of China/ GR - 81770126/National Natural Science Foundation of China/ GR - 82000218/National Natural Science Foundation of China/ PT - Journal Article PT - Meta-Analysis DEP - 20220611 PL - Germany TA - Ann Hematol JT - Annals of hematology JID - 9107334 RN - 0 (Phosphoinositide-3 Kinase Inhibitors) SB - IM MH - Humans MH - *Lymphoma/drug therapy MH - *Neoplasms MH - *Neutropenia MH - Phosphatidylinositol 3-Kinases MH - Phosphoinositide-3 Kinase Inhibitors OTO - NOTNLM OT - Adverse event OT - Lymphoma patients OT - Meta-analysis OT - Phosphoinositide 3 kinase inhibitors EDAT- 2022/06/11 06:00 MHDA- 2022/07/16 06:00 CRDT- 2022/06/10 23:21 PHST- 2022/02/01 00:00 [received] PHST- 2022/05/23 00:00 [accepted] PHST- 2022/06/11 06:00 [pubmed] PHST- 2022/07/16 06:00 [medline] PHST- 2022/06/10 23:21 [entrez] AID - 10.1007/s00277-022-04876-x [pii] AID - 10.1007/s00277-022-04876-x [doi] PST - ppublish SO - Ann Hematol. 2022 Aug;101(8):1741-1753. doi: 10.1007/s00277-022-04876-x. Epub 2022 Jun 11.